Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 1922

Sort by

Sort Order Select

Journal Articles

TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation

Konstantinos Lontos, Rima M. Saliba, Rashmi Kanagal-Shamanna, Gonca Özcan, Jeremy Ramdial, George Chen, Tapan Kadia, Nicholas James Short, Naval G. Daver, Hagop Kantarjian, David Marin, Partow Kebriaei, Uday Popat, Richard Champlin, Elizabeth Shpall, Betül Oran

Blood Adv (2025) 9 (11): 2845–2854.

https://doi.org/10.1182/bloodadvances.2024014499

Published: 2025

Journal Articles

Improved outcomes and treatment guidance in pediatric therapy-related AML: AML-BFM study group recommendations

Stephanie Sendker, Markus Schneider, Evangelia Antoniou, Daniel Neumann, Naghmeh Niktoreh, Uta Dirksen, Nils von Neuhoff, Ursula Creutzig, Dirk Reinhardt, Katharina Waack

Blood Adv (2025) 9 (11): 2831–2841.

https://doi.org/10.1182/bloodadvances.2024014728

Published: 2025

Includes: Supplemental data

Journal Articles

On the road to improved therapies for therapy-related AML

Alexandra McLean Stevens, Todd M. Cooper

Blood Adv (2025) 9 (11): 2842–2844.

https://doi.org/10.1182/bloodadvances.2025015987

Published: 2025

Journal Articles

A cure for the kiss of death?

Jacob S. Appelbaum, Mary-Elizabeth Percival, Bart L. Scott

Blood Adv (2025) 9 (11): 2855–2856.

https://doi.org/10.1182/bloodadvances.2025015850

Published: 2025

Journal Articles

Prebiotic fibre enteral supplementation post allogeneic transplantation; feasibility and impact on the microbiome

Sarah Andersen, PhD, Adv APD, Glen A Kennedy, Merrilyn Banks, Bernadine Mary Flanagan, BSc (Hons) PhD, Andrea S Henden

Blood Adv bloodadvances.2024015703.

https://doi.org/10.1182/bloodadvances.2024015703

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of Concomitant Azoles on Ruxolitinib Treatment in Patients With GVHD: Post Hoc Analyses of REACH2 and REACH3

Zahra Mahmoudjafari, Emily Kintsch, Zhenyi Xue, Valkal Bhatt, John Galvin, Franco Locatelli, Robert Zeiser

Blood Adv bloodadvances.2025016212.

https://doi.org/10.1182/bloodadvances.2025016212

Published: 2025

Journal Articles

Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia

Blood Adv bloodadvances.2025016513.

https://doi.org/10.1182/bloodadvances.2025016513

Published: 2025

Journal Articles

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy

Blood Adv (2025) 9 (11): 2763–2772.

https://doi.org/10.1182/bloodadvances.2024014846

Published: 2025

Includes: Supplemental data

Journal Articles

Safety, efficacy, and treatment satisfaction in adults with ITP who switched to avatrombopag from another TPO-RA

Michael D. Tarantino, Kailash Mosalpuria, Scott Kolodny, Jessica Zhang, Michael Vredenburg, Brian D. Jamieson

Blood Adv (2025) 9 (11): 2733–2743.

https://doi.org/10.1182/bloodadvances.2024015635

Published: 2025

Includes: Supplemental data

Journal Articles

Infection after CD19 chimeric antigen receptor T cell therapy for large B cell lymphoma: Real-world analysis from CIBMTR

Blood Adv bloodadvances.2025016141.

https://doi.org/10.1182/bloodadvances.2025016141

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of HLA alloimmunization on clinical outcomes of severe aplastic anemia treated with immunosuppressive therapy

Jibran Durrani, Leonard N. Chen, Ruba N. Shalhoub, Valentina Baez, Joshua Glass, Nu Ri Cha, Xiaoyang Ma, Zhijie Wu, Shouguo Gao, Jennifer Lotter, Olga Rios, Colin O. Wu, Willy A. Flegel, Neal S. Young, Emma M. Groarke, Bhavisha A. Patel

Blood Adv (2025) 9 (11): 2639–2650.

https://doi.org/10.1182/bloodadvances.2024015301

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation

Blood Adv (2025) 9 (10): 2570–2584.

https://doi.org/10.1182/bloodadvances.2024014177

Published: 2025

Journal Articles

Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non–low-risk AML

Blood Adv (2025) 9 (10): 2542–2552.

https://doi.org/10.1182/bloodadvances.2024014901

Published: 2025

Includes: Supplemental data

Journal Articles

Characterization and treatment outcomes of malignant histiocytoses in a retrospective series of 141 cases in France

Blood Adv (2025) 9 (10): 2530–2541.

https://doi.org/10.1182/bloodadvances.2024015208

Published: 2025

Includes: Supplemental data

Journal Articles

Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation

Blood Adv (2025) 9 (10): 2553–2569.

https://doi.org/10.1182/bloodadvances.2024014879

Published: 2025

Includes: Supplemental data

Journal Articles

Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study

Jason Westin, Tycel J. Phillips, Amitkumar Mehta, Marc S. Hoffmann, Eva Gonzalez-Barca, Catherine Thieblemont, Mariana Bastos-Oreiro, Richard Greil, Sebastian Giebel, Michael C. Wei, Jue Wang, Reinhard Bucher, Jason Sit, Elicia Penuel, Enkhtsetseg Purev, Donald L. Yee, Juan Miguel Bergua-Burgues

Blood Adv (2025) 9 (10): 2461–2472.

https://doi.org/10.1182/bloodadvances.2024014907

Published: 2025

Includes: Supplemental data

Journal Articles

Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study

Bei Hu, Patrick M. Reagan, Laurie H. Sehn, Jeff P. Sharman, Mark Hertzberg, Huilai Zhang, Austin Kim, Charles Herbaux, Lysiane Molina, Dai Maruyama, Frank Stenner, Saibah Chohan, Rucha Kothari, Connie Lee Batlevi, Jamie Hirata, Deniz Sahin, Calvin Lee, Matthew Sugidono, Hervé Tilly

Blood Adv (2025) 9 (10): 2489–2499.

https://doi.org/10.1182/bloodadvances.2024014707

Published: 2025

Includes: Supplemental data

Journal Articles

Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia

Valentin Goede, Kirsten Fischer, Sandra Robrecht, Adam Giza, Martin J. S. Dyer, Michael J. Eckart, Lothar Mϋller, Lukáš Smolej, Nadine Kutsch, Anna-Maria Fink, Stephan Stilgenbauer, Michael Hallek

Blood Adv (2025) 9 (10): 2431–2435.

https://doi.org/10.1182/bloodadvances.2024014875

Published: 2025

Includes: Supplemental data

Journal Articles

Impacts of donor age and HLA mismatch on HCT outcomes differ according to the donor CMV serostatus in unrelated allo-HCT

Shunto Kawamura, Daishi Nakagawa, Takashi Nagayama, Yuta Katayama, Noriko Doki, Wataru Takeda, Tetsuya Nishida, Ken-ichi Matsuoka, Takashi Ikeda, Hiroyuki Ohigashi, Masashi Sawa, Kentaro Fukushima, Junya Kanda, Kentaro Serizawa, Makoto Onizuka, Takahiro Fukuda, Yoshiko Atsuta, Yoshinobu Kanda, Hideki Nakasone

Blood Adv (2025) 9 (9): 2356–2365.

https://doi.org/10.1182/bloodadvances.2024014408

Published: 2025

Includes: Supplemental data

Journal Articles

Improved survival with model-based dosing of antithymocyte globulin in pediatric hematopoietic cell transplantation

Rick Admiraal, Stefan Nierkens, Marc B. Bierings, Mirjam E. Belderbos, Alwin D. Huitema, Robbert G. M. Bredius, Yilin Jiang, Kevin J. Curran, Andromachi Scaradavou, Maria I. Cancio, Elizabeth Klein, Wouter J. Kollen, Dorine Bresters, Friso G. J. Calkoen, A. Birgitta Versluijs, C. Michel Zwaan, Jaap Jan Boelens, Caroline A. Lindemans

Blood Adv (2025) 9 (9): 2344–2353.

https://doi.org/10.1182/bloodadvances.2024014836

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation

Improved outcomes and treatment guidance in pediatric therapy-related AML: AML-BFM study group recommendations

On the road to improved therapies for therapy-related AML

A cure for the kiss of death?

Prebiotic fibre enteral supplementation post allogeneic transplantation; feasibility and impact on the microbiome

Impact of Concomitant Azoles on Ruxolitinib Treatment in Patients With GVHD: Post Hoc Analyses of REACH2 and REACH3

Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia

Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy

Safety, efficacy, and treatment satisfaction in adults with ITP who switched to avatrombopag from another TPO-RA

Infection after CD19 chimeric antigen receptor T cell therapy for large B cell lymphoma: Real-world analysis from CIBMTR

Impact of HLA alloimmunization on clinical outcomes of severe aplastic anemia treated with immunosuppressive therapy

Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation

Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non–low-risk AML

Characterization and treatment outcomes of malignant histiocytoses in a retrospective series of 141 cases in France

Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation

Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study

Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study

Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia

Impacts of donor age and HLA mismatch on HCT outcomes differ according to the donor CMV serostatus in unrelated allo-HCT

Improved survival with model-based dosing of antithymocyte globulin in pediatric hematopoietic cell transplantation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only